Metastatic and triple-negative breast cancer: challenges and treatment options
Top Cited Papers
Open Access
- 5 July 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Delivery and Translational Research
- Vol. 8 (5), 1483-1507
- https://doi.org/10.1007/s13346-018-0551-3
Abstract
The major current conventional types of metastatic breast cancer (MBC) treatments include surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing biological drugs, targeted treatment and gene therapy can potentially reduce the mortality and improve the quality of life in patients with MBC. However, combination of several types of treatment is usually recommended. Triple negative breast cancer (TNBC) accounts for 10–20% of all cases of breast carcinoma and is characterized by the low expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). Consequently, convenient treatments used for MBC that target these receptors are not effective for TNBC which therefore requires special treatment approaches. This review discusses the occurrence of MBC, the prognosis and predictive biomarkers of MBC, and focuses on the novel advanced tactics for treatment of MBC and TNBC. Nanotechnology-based combinatorial approach for the suppression of EGFR by siRNA and gifitinib is described.Keywords
Funding Information
- National Cancer Institute (CA138533)
This publication has 246 references indexed in Scilit:
- Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancerCancer Chemotherapy and Pharmacology, 2013
- Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?Cancer Chemotherapy and Pharmacology, 2012
- A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerBreast Cancer Research and Treatment, 2012
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumabBreast Cancer Research and Treatment, 2012
- Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast CancerPharmaceutical Research, 2011
- Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic VariablesPathology and Oncology Research, 2011
- Characteristics of triple-negative breast cancerZeitschrift für Krebsforschung und Klinische Onkologie, 2010
- Systemic Spread Is an Early Step in Breast CancerCancer Cell, 2008
- Metastasis genes: A progression puzzleNature, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002